Superblood: The Development of Novel Red-Cell Therapeutics
Dec 16, 2017 ·
33m 27s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics. Epstein explains how his company...
show more
In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics.
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
show less
Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Information
| Author | Peter Hofland |
| Organization | Peter Hofland |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
